HAYWARD, Calif.--(BUSINESS WIRE)--Impax Laboratories, Inc. (NASDAQ: IPXL) today confirms that it has initiated a challenge of the patents listed in the Orange Book in connection with Atelvia® (Risedronate sodium) delayed-release tablets, 35 mg.
Help employers find you! Check out all the jobs and post your resume.
